ENDRA Life Sciences Receives CE Mark for its TAEUS(R) Clinical Product Targeting Non-Alcoholic Fatty Liver Disease
First regulatory clearance paves the way to commercialize TAEUS in European markets U.S. FDA submission expected during H1:20 ANN ARBOR,...